BACKGROUND: Cancer pain is a complex, debilitating symptom involving both nociceptive mechanisms from tissue damage, tumour acidification, and pro-inflammatory mediators, and neuropathic components from tumour invasion, chemo- or radiation-induced nerve injury, altered ion channels, and glial activation. This peripheral and central sensitisation makes conventional analgesics inadequate and toxic. OBJECTIVES AND METHODOLOGY: Engineered small extracellular vesicles (EVs) can offer a promising nanomedicine solution. These biocompatible, nanoscale vesicles cross biological barriers, including the blood-brain barrier, and can be loaded with therapeutic cargo like anti-inflammatory miRNAs, neurotrophic factors, or analgesics via parent cell engineering or direct loading and functionalization. CONCLUSION: Targeted EV delivery can enable localised suppression of pro-nociceptive inflammation, nerve repair, precise analgesic release, and tumour burden reduction, addressing cancer pain's molecular mechanisms for more effective pain relief.
Sarkar et al. (2026) studied this question.